Cargando…
Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature
Background: pediatric patients with inflammatory bowel diseases (IBD) who qualify for biological therapy represent a group of severely ill patients. They have never been successful with conventional medication. Biologic medications in monotherapy are frequently used in the disease course, however th...
Autores principales: | Wlazło, Magdalena, Kierkuś, Jarosław |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000175/ https://www.ncbi.nlm.nih.gov/pubmed/35407612 http://dx.doi.org/10.3390/jcm11072004 |
Ejemplares similares
-
Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study
por: Wlazło, Magdalena, et al.
Publicado: (2022) -
Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019) -
Biological markers of disease activity in inflammatory bowel diseases
por: Szymanska, Edyta, et al.
Publicado: (2023) -
Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases
por: Fabiszewska, Sylwia, et al.
Publicado: (2021) -
The risk of cardiovascular complications in inflammatory bowel disease
por: Czubkowski, Piotr, et al.
Publicado: (2020)